PamGene and it’s collaborators presented exciting posters at the Annual Meeting of the American Association of Cancer Research in Philadelphia, Pennsylvania (April 18th to 22nd, 2015).
Session: Tuesday, Apr 21, 2015, 1:00 PM- 5:00 PM, Section 25, Poster Board 25
Hilhorst et al have shown that serine/threonine kinase activity profiling appears to be able to differentiate benign and malignant thyroid tumors. Ex vivo spiking in of kinase inhibitors showed differential inhibition in tumors with a somatic BRAF mutation. Potentially, an industrial prediction platform can be envisioned for testing of novel drugs in tumor tissue. Whether individual patient responses against registered kinase inhibitors can be predicted must be investigated.
Session: Monday, Apr 20, 2015, 1:00 PM- 5:00 PM, Section 22, Poster Board 04
Ruijtenbeek et al* have shown the feasibility of predicting clinical response to sunitinib based on ex vivo drug response in metastatic renal cell carcinoma (mRCC) using kinase activity profiling. This requires further investigation with a larger sample set. Furthermore, the ex vivo response to a drug panel (sunitinib, axitinib, sorafenib, pazopanib, erlotinib and crenolanib) suggests that identification of novel treatment options for nonresponders might be feasible.
* This study has received funding from the European Union’s Seventh Framework Programme (FP7/20072013) under grant agreement no 259939.
Session: Sunday, Apr 19, 2015, 1:00 PM- 5:00 PM, Section 14, Poster Board 11
Willey et al* have identified kinomic alterations that may correlate MicroTumor and patient tumor biology and guide the use of molecularly targeted SMIs. They believe that such a two-stage approach (Microtumor screening to predict PDX sensitivities) will improve preclinical drug screening in GBM and other cancers.
- If you would like to discuss potential interest in PamGene’s kinase activity profiling studies, or
- You would like to discuss the posters that were presented at the AACR, please contact:
Riet Hilhorst, Senior Scientist: firstname.lastname@example.org